Associated equity: Cantargia
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme, the most advanced being a Phase IIa CANFOUR trial for pancreatic cancer and non-small cell lung cancer. CAN10 is being developed for systemic sclerosis and myocarditis, with clinical development expected to start in early 2022.
In this video, the company’s chief executive officer Göran Forsberg provides an update on R&D progress, including a summary of the promising results Cantargia recently reported from the pancreatic cancer arm of the CANFOUR trial.
Get access to the very latest content matched to your personal investment style.